Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET
A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy
Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL...
Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs
Agenus Inc. (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before...
Integrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional biomarkers
Agenus Inc . ( Nasdaq: AGEN ), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program...
Medical Affairs scale-up supports France’s multi-tumor AAC access framework and expanding paid named-patient programs requests
Access to Acceleration: Agenus’ BOT+BAL Global Momentum Entering 2026 Webcast on Wednesday, January 28, 2026, at 4:00 p.m. ET